摘要
炎症反应是生物体在进化过程中选择的一套复杂的防御体系,能激发适当的应答。然而手术和创伤可能诱发过度炎症级联反应,导致严重损伤甚至死亡。肝脏手术后的过度炎症反应可能更为显著和关键。该文提醒广大临床医生要高度重视研究过度炎症反应的损害与广泛肝切除的关系以及过度炎症反应对肝切除后剩余肝的损害。初期的抗炎症介质治疗研究主要集中在各种促炎因子的抗体、受体拮抗剂和竞争性受体拮抗剂上。本文介绍了美国FDA批准的第一个有关治疗严重败血症的药物(DrotrecoginAlfa),也介绍了作者在阻断肝切除后过度炎症反应、保护剩余肝细胞方面的实验研究。
Inflammatory response forms a series of complicated defense system that has been chosen by human being during a long-term evolution. This system evokes suitable reaction to achieve the new balance. Surgery and trauma may induce overwhelming inflammatory cascade, which could cause severe complications and even death. This kind of inflammation following liver surgery may present clearer and more importantly. The earlier anti-inflammatory medium treatments had been concentrated to the antibodies, inhibitors, and receptor antagonists of pro-inflammatory factors. The later developed Drotrecogin Alfa (active) is a recombinant human active Protein C, which is the first product approved by FDA in the US. Recently, we have employed intracellular signaling inhibitor AG-490 and P21-Ras blocker Atorvastatin in an animal model, and ulinastatin in the patient following liver surgery. The primary results suggested a promising outcome.
出处
《基础医学与临床》
CSCD
北大核心
2005年第3期199-203,共5页
Basic and Clinical Medicine
